Journal
NATURE COMMUNICATIONS
Volume 13, Issue 1, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41467-022-34000-6
Keywords
-
Categories
Funding
- Netherlands Organization for Scientific Research (NWO: Cancer Genomics Netherlands) [VICI 91814643, VICI 91819616, VIDI 91713334]
- European Research Council (ERC Synergy project CombatCancer)
- ERC-Consolidator grant TENSION
- NWO
- Dutch Cancer Society [KWF13191, KWF10623]
- Swiss National Science foundation
- Hanarth Fonds
- ERC [615300]
- European Research Council (ERC) [615300] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
MYC plays a crucial role in suppressing anti-tumour immunity in triple-negative breast cancer by directly regulating the transcription of interferon signalling genes. MYC overexpression decreases lymphocyte infiltration in tumors and prevents the recruitment and activation of immune cells. These findings reveal the mechanisms by which MYC overexpression leads to poor immunogenicity in triple-negative breast cancer.
Tripe-negative breast cancers poorly respond to immune checkpoint inhibition therapy, due to their immune-hostile tumour microenvironment. Authors here show that the oncogene MYC plays a pivotal role in suppressing anti-tumour immunity via directly regulating the transcription of interferon signalling genes. The limited efficacy of immune checkpoint inhibitor treatment in triple-negative breast cancer (TNBC) patients is attributed to sparse or unresponsive tumor-infiltrating lymphocytes, but the mechanisms that lead to a therapy resistant tumor immune microenvironment are incompletely known. Here we show a strong correlation between MYC expression and loss of immune signatures in human TNBC. In mouse models of TNBC proficient or deficient of breast cancer type 1 susceptibility gene (BRCA1), MYC overexpression dramatically decreases lymphocyte infiltration in tumors, along with immune signature remodelling. MYC-mediated suppression of inflammatory signalling induced by BRCA1/2 inactivation is confirmed in human TNBC cell lines. Moreover, MYC overexpression prevents the recruitment and activation of lymphocytes in both human and mouse TNBC co-culture models. Chromatin-immunoprecipitation-sequencing reveals that MYC, together with its co-repressor MIZ1, directly binds promoters of multiple interferon-signalling genes, resulting in their downregulation. MYC overexpression thus counters tumor growth inhibition by a Stimulator of Interferon Genes (STING) agonist via suppressing induction of interferon signalling. Together, our data reveal that MYC suppresses innate immunity and facilitates tumor immune escape, explaining the poor immunogenicity of MYC-overexpressing TNBCs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available